

Please note this meeting will be recorded

This recording and all paper and electronic copies of materials presented or shared on the screen will be subject to Vermont's public records act, 1 V.S.A. §§ 315 et seq., and will be made available to the general public upon request.

Participants are responsible for ensuring that no confidential or proprietary information is presented or discussed in the meeting and associated materials.



Vaccines, Science & Program Updates: Quarterly Vaccine Provider Call

Katie Mahuron, RN – *Adult Nurse Coordinator*

Meghan Carey, RN – *Child & Adolescent Nurse Coordinator*

January 15, 2026

Today's Agenda

- **Program Updates**
 - **Re-enrollment Updates – Samantha Madison, VFC Coordinator**
- **Vaccine History**
- **Childhood Immunization Schedule**



Reminder: RSV Vaccine Administration Timeline

- Last day to administer Abrysvo vaccine to pregnant individuals is January 31.
- Infants who do not receive protection through maternal vaccination (Abrysvo) should receive a RSV monoclonal antibody product.



Re-Enrollment

Samantha Madison, VFC Coordinator

Important to remember.

Re-enrollment is due every January, this year is a full enrollment

- Medical Directors sign the provider agreements
- List of all prescribing doctors at the practice.
- In addition to the provider profile which includes items like patient numbers.



Friday January 30th, 2026

Update your Patient Population

Provider Population

Provider population is based on patients seen during the previous 12 months. Report the number of children by age group who received vaccinations at your facility. Count a child only once based on the age/eligibility categories at the last immunization visit, regardless of the number of visits made. The following table details the number of children who received VFC vaccine and non-VFC vaccine by eligibility category.

VFC vaccine eligibility categories: # of children by age and category who received VFC vaccine

VFC Eligibility Categories	< 1 year	1-6 years	7-18 years	Total 0-18 years
Medicaid				0
No Insurance				0
American Indian/Alaskan Native				0
Underinsured FQHC/RHC or Deputized Facility*				0
Total VFC	0	0	0	0

Non-VFC vaccine eligibility categories: # of children by age and category who received non-VFC vaccine

Non-VFC Eligibility Categories	< 1 year	1-6 years	7-18 years	Total 0-18 years
Patients covered fully through health insurance (covered by state universal vaccine plan)				0
Other Underinsured**				0
Patients covered by Children's Health Insurance Program (CHIP)***				0
Total Non-VFC	0	0	0	0

Total Patients	< 1 year	1-6 years	7-18 years	Total 0-18 years
Total (sum of Total VFC + Total non-VFC)	0	0	0	0

The numbers in there are from last year and need to be updated

Adult Population Served

Insurance Type, Ages	19-34 Years	35-49 Years	50-64 Years	65+ Years	Total
No Health Insurance					0
Underinsured*					0
Fully Insured					0
Total	0	0	0	0	0

* A person who has health insurance, but the insurance does not include any vaccines; a person whose insurance cover only selected vaccines; a person whose insurance does not provide first-dollar coverage for vaccines.

Common Issues

Medical Director needs to match EXACTLY Facility Form:

Medical Director Or Equivalent

Instructions: The official, VFC-registered health care provider signing the agreement must be a practitioner authorized to administer pediatric vaccines* under state law, who will also be held accountable for compliance by the entire organization and its VFC providers, with the responsible conditions outlined in the provider enrollment agreement. The individual listed here must sign the provider agreement.

**Note: For the purposes of the VFC program, the term "vaccine" is defined as any FDA-authorized or licensed, ACIP-recommended product for which ACIP approves a VFC resolution for inclusion in the VFC program.*

First Name	Middle Name	Last Name	Medical Director Title
Rick	Alan	Hildebrant	MD

Agreements:

By signing this form, I certify on behalf of myself and all immunization providers in this facility, I have read and agree to the Vaccines for Children enrollment requirements listed above and understand I am accountable (and each listed provider is individually accountable) for compliance with these requirements.

Medical Director or Equivalent	Agreement Date
Rick Alan Hildebrant	1/5/2026

Second Individual as Needed	Agreement Date
-----------------------------	----------------

Common Issues

Medical Director needs to match EXACTLY Facility Form:

Medical Director Or Equivalent

Instructions: The official, VFC-registered health care provider signing the agreement must be a practitioner authorized to administer pediatric vaccines under state law, who will also be held accountable for compliance by the agreement. The individual listed here must sign the provided form.*

**Note: For the purposes of the VFC program, the term "vaccine" includes any vaccine that is included on the state's immunization schedule for inclusion in the VFC program.*

First Name	Middle Name
Rick	Alan

Medical Director or Equivalent

By signing this form, I certify on behalf of myself And all immunization providers in this facility, that I have read and agree to the Vermont Adult Vaccine Program requirements listed above and understand that I am accountable (And each listed provider Is individually accountable) for compliance with these requirements.

Medical Director or Equivalent	Agreement Date
<input type="text" value="Rick Hildebrant, MD"/>	<input type="text" value="1/5/2026"/>
The VAVP agreement must be acknowledged by the Medical Director and/or Second Individual noted on your practice facility form for this enrollment period.	
Second Individual as Needed	Agreement Date
<input type="text"/>	<input type="text"/>


By signing this form, I certify on behalf of myself and all immunization providers in this facility, that I have read and agree to the Vermont Adult Vaccine Program requirements listed above and understand that I am accountable (And each listed provider Is individually accountable) for compliance with these requirements.

Medical Director or Equivalent	Agreement Date
Rick Alan Hildebrant	1/5/2026
Second Individual as Needed	Agreement Date
<input type="text"/>	<input type="text"/>


Agreements:

Purpose

Recap: February 2025 – January 2026




Responding to Immunization Changes: Our Goals



Immunization History

Timeline of Routine Vaccine Availability: Building Trust Through History



Development of Childhood Immunization Schedules & Current Landscape




1940's – American Academy of Pediatrics Committee on Infectious Diseases published early vaccine guidance and schedules



1964 – U.S. Surgeon General establishes ACIP



1995 – First harmonized childhood immunization schedule published by ACIP, AAP & AAFP



Now – Two schedules are available (AAP & CDC/ACIP)

[How Vaccine Schedules Changed Over Time & Why - HealthyChildren.org](https://www.healthychildren.org/How-Vaccine-Schedules-Changed-Over-Time-Why)

Routine Childhood Immunization Schedules Today

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN®



17 Routine Immunizations

Timed doses to protect children before potential exposure to infection

Designed for U.S. specific disease risk

Recommended at ages when the immune system responds most effectively

Aligns with routine well-child visits



U.S. CENTERS FOR DISEASE
CONTROL AND PREVENTION

11 Routine Immunizations

Developed based on review of other countries

Reduces the number of routinely recommended vaccines

American Academy of Pediatrics

Vermont is following the AAP Childhood Immunization Schedule

[AAP-Immunization-
Schedule.pdf](#)



Vermont Department of Health

Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger

United States
2025

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN®



Vaccines and Other Immunizing Agents in the Child and Adolescent Immunization Schedule®

Monoclonal antibody	Abbreviation(s)	Trade name(s)
Respiratory syncytial virus monoclonal antibody	RSV-mAb	Beyfortus Enflonsia
Vaccine	Abbreviation(s)	Trade name(s)
COVID-19 vaccine	1vCOV-mRNA	Comirnaty mNEXS/PIKE
	1vCOV-aPS	Nuvaxovid
Dengue vaccine	DEN4CYD	Dengvaxia
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel Infanrix
Haemophilus influenzae type b vaccine	Hib (PRP-T)	ActHIB
	Hib (PRP-OMP)	Hiberix PedvaxHIB
Hepatitis A vaccine	HepA	Havrix Vaqta
Hepatitis B vaccine	HepB	Engerix-B Recombivax HB
Human papillomavirus vaccine	HPV	Gardasil 9
Influenza vaccine (inactivated: egg-based)	IIV3	Multiple
Influenza vaccine (inactivated: cell-culture)	cdIIV3	Flucelvax
Influenza vaccine (recombinant)	RIV3	Flublok
Influenza vaccine (live, attenuated)	LAIV3	FluMist
Measles, mumps, and rubella vaccine	MMR	M-M-R II Priorix
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-CRM	Menveo
	MenACWY-TT	MenQuadfi
Meningococcal serogroup B vaccine	MenB-4C	Bexsero
	MenB-FHbp	Trumenba
Meningococcal serogroup A, B, C, W, Y vaccine	MenACWY-TT/MenB-FHbp	Penbraya
	MenACWY-CRM/MenB-4C	Penmenv
Mpox vaccine	Mpox	JYNNEOS
Pneumococcal conjugate vaccine	PCV15	Vaxneuvance
Pneumococcal polysaccharide vaccine	PPSV20	Pneumovax 20
Poliovirus vaccine (inactivated)	PPSV23	Pneumovax 23
Respiratory syncytial virus vaccine	IPV	Ipel
Rotavirus vaccine	RSV	Abrysvo
	RV1	Rotarix
	RV5	RotaTeq
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel Boostrix
Tetanus and diphtheria vaccine	Td	Tenivac
Varicella vaccine	VAR	Tdavax Varivax
Combination vaccines (use combination vaccines instead of separate injections when appropriate)		
DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine	DTaP-IPV/Hib	Pentacel
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix Quadacel
DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine	DTaP-IPV-Hib-HepB	Vaxelis
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit when indicated. The use of trade names is for identification purposes only and does not imply endorsement by the AAP.

Updated November 21, 2025

How to use the child and adolescent immunization schedule

- 1 Determine recommended vaccine by age (Table 1)
- 2 Determine recommended interval for catch-up vaccination (Table 2)
- 3 Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
- 4 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- 5 Review contraindications and precautions for vaccine types (Appendix)
- 6 Review new or updated American Academy of Pediatrics (AAP) guidance (Addendum)

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov (Accessed August 11, 2025) or 800-822-7967
- For RSV-mAb products, clinically significant adverse events to MedWatch Adverse Event Report Program at www.accessdata.fda.gov/scripts/medwatch/index.cfm (Accessed August 11, 2025). If co-administered with other products, then report to VAERS.

Questions or comments

Submit a question or comment to www.aap.org/en/forms/immunization-schedule-questions.


Helpful information

- Best practices for immunization (including contraindications and precautions): www.aap.org/immunization and www.immunize.org
- Red Book: 2024–2027 Report of the Committee on Infectious Diseases (33rd Edition): www.aapRedBook.org
- Vaccine information statements: www.immunize.org/vaccines/vis/about-vis

For the most up-to-date version,
visit AAP.org/ImmunizationSchedule



Debunking Common Misconceptions









Misconception: Peer countries, such as Denmark, recommend children receive fewer vaccines.

Fact 1: Denmark is the outlier.

Fact 2: The United States is not Denmark; vaccine recommendations are made based on individual countries' unique disease patterns, healthcare system and public health priorities.

- The AAP schedule (17) is similar to Australia (15), Canada (16), France (15) and Germany (15).
- Our "peer" countries have different healthcare systems and social infrastructures that impact their recommendations.

United States vs. Denmark

	Denmark	United States
	6 million	340 million
	Mainland Denmark: 16,639 sq mi Kingdom of Denmark: 2.2 million sq mi	3,794,080 sq mi
	Universal (free) health care	8% of population uninsured 5-6% of children uninsured
	Highly integrated health information system with linkage across data sources.	Complex series of individual data registries and electronic health systems with limited communication across systems
	46 weeks of paid parental leave	Up to 12 weeks unpaid parental leave through FMLA
	Free college education	Limited federal income-based grants and loans



Vermont's Path Forward

Vermont Clinical Guidance and Implementation

No changes to
Vermont's
current clinical
practice.

No changes to
vaccine ordering

State aligns with
AAP
immunization
schedule

No changes to
childcare/school
vaccine
requirements.



Vermont Child Care and School Requirements

- Immunization requirements for Vermont childcare providers and schools **remain the same**
- Children must be up-to-date on all age-appropriate immunizations as outlined in the Vermont vaccination schedule
- No changes to provisional admittance, medical, and religious exemptions


Age When Enrolling:	Immunizations Required:
2-3 months	1 each of DTaP, Hep B, Polio, Hib, PCV
4-5 months	2 each of DTaP, Hep B, Polio, Hib, PCV
6-14 months	3 each of DTaP, Hep B, Polio, Hib, PCV
15-17 months	3 each of DTaP, Hep B, Polio 1-4 doses each of Hib and PCV 1 each of MMR and Varicella
18 months- 4 years	4 DTaP, 3 each of Hep B and Polio 1-4 doses each of Hib and PCV 1 each of MMR and Varicella

DTaP: diphtheria, tetanus, pertussis • Hep B: hepatitis B • Polio • Hib: Haemophilus influenzae b PCV: pneumococcal • MMR: measles, mumps, rubella • Varicella: chickenpox
Hepatitis A, COVID-19, rotavirus, and influenza vaccines are also strongly recommended, but are not required.

[Immunization Information for Child Care and School Providers | Vermont Department of Health](#)

[2025-2026 School Year Immunization Requirements](#)

Debunking Common Misconceptions



Misconception: Vermont is taking a new approach around the way immunizations are recommended

Fact: Vermont is following science

- Vermont has *not* changed its approach.
- The CDC recommendations have diverged from the traditional process and approach.
 - CDC recommendations changed without any new scientific evidence on vaccine safety or public benefit.
 - No re-evaluation of disease burden, morbidity/mortality trends or cost-effectiveness published.
- **Disease risk has not changed.**

Identifying & Responding to the Gaps

Vermont Required and Recommended Child and Teen Vaccination Schedule

Vermont Required and Recommended Child & Teen Vaccination Schedule December 2025

Vaccine	Birth	2 Months	4 Months	6 Months	12-15 Months	15-18 Months	Required Prior to Kindergarten	Required Prior to 7th Grade	13-18 Years
Required for Child Care									
Required for School									
Recommended									
Haemophilus influenzae type b (Hib)		Hib	Hib	Hib	Hib				
Pneumococcal (PCV)		PCV	PCV	PCV	PCV				
Hepatitis B (HepB)	HepB	HepB	HepB	HepB					
Diphtheria, Tetanus, Pertussis (DTaP)		DTaP	DTaP	DTaP					
Poliovirus (Polio) (IPV)		IPV	IPV	IPV					
Measles, Mumps, Rubella (MMR)					MMR				
Varicella (Chicken Pox) ¹					Varicella				
Tetanus, Diphtheria, Pertussis (Tdap)								Tdap	
Meningococcal ACWY (MCV4) ²								MCV4	MCV4 second dose, at age 16
Meningococcal B (MenB) ³									MenB 2 doses, age 16-18
Hepatitis A (HepA)									
Rotavirus (RV1 or RV5)		RV1/RV5	RV1/RV5	RV5					HPV 2 or 3 doses ⁴
Human Papillomavirus (HPV)									
Influenza									
COVID-19									
RSV									

¹ Vaccine or documentation of history of disease.
² Recommended for all. Required only for residential students entering 7th grade newly enrolled in 8-12.
³ Recommendation for MenB vaccine is based on clinical discretion. Beginning at age 16, two doses at least one month apart.
⁴ If you start the series before age 15, only 2 doses are recommended. If you start after age 15 or are immunocompromised, then 3 doses are recommended.
⁵ Recommendation for children 8-19 months old who are at high risk for severe RSV during their second RSV season.

Vermont's immunization schedule is compatible with the current recommendations of the American Academy of Pediatrics (AAP).
 For more information, contact the Vermont Department of Health Immunization Program:
 Phone: 800-635-7638 • Toll free (in VT): 800-640-4374 Website: HealthVermont.gov

Immunization Registry (IMR) Forecaster

Programs:
Immunization Registry
Patient Reports
Immunization Record
Objections and Contraindications
Print Forecaster Results
Vaccine Administration Record
VFC Assessment Report

- Plan is to align Forecaster with Vermont/AAP recommendations.
- Collaborating with national partners who utilize same Forecaster base coding
 - Commitment has been made to maintain universal recommendation for Hep B birth dose

Legislation is in Process

The way we fund and purchase vaccines through the Immunization Program is written in statute

There is a need for statutory change to:

- Create a clear and transparent process for issuing immunization recommendations that follows the science
- Allow for flexibility to purchase recommended immunizations from any source
- Ensure private health insurers continue to cover recommended immunizations
- Address potential barriers faced by health care providers to prescribe and administer recommended immunizations

Impacts of H. 545

- Vermont will have flexibility to follow vaccination schedules from CDC & ACIP and/or professional medical organizations like AAP, AAFP, ACOG
- Immunization Program will continue to purchase recommended vaccines at the lowest available cost and have flexibility to select the vendor
- Insurers will continue to cover recommended vaccines at no cost
- Pharmacists and pharmacy techs will be able to administer recommended vaccines
- Commissioner of Health will be able to issue a standing order that health care professionals can rely on to administer recommended vaccines
- Health care providers will have liability protection for administering recommended vaccines

[H-0545 As Introduced.pdf](#)

Childhood Immunization Recommendations

Strong Recommendations

Percent who say they have a **great deal or a **fair amount** of trust in the following to provide reliable information about vaccines:**



Note: *Among parents or guardians of a child under the age of 18 living in their household. See topline for full question wording.

Source: KFF Tracking Poll on Health Information and Trust (September 23-29, 2025) • [Get the data](#) • [Download PNG](#)

KFF

Rotavirus

- Spread through direct contact with an infected person or contaminated surfaces
- Symptoms can last 3-8 days
 - Severe Diarrhea
 - Vomiting
 - Dehydration
 - Stomach Pain
 - Fever
 - Electrolyte Imbalance

Source: [Rotavirus: The Disease & Vaccines](#)



55,000-70,000
before vaccines



80%

11,000-14,000
after vaccines

Rotavirus Immunization Recommendation

Two or Three-dose series (oral)

- Rotarix: 2-dose series at 2 and 4 months of age
- RotaTeq: 3-dose series at 2, 4 and 6 months of age

Side effects:


- Fussiness
- Diarrhea
- Vomiting



Hepatitis B

- Spread through contact with infected blood and bodily fluids
- Symptoms are often silent. When present, may include:

Fatigue	Abdominal Pain
Appetite loss	Nausea
Vomiting	Jaundice



**Childhood infections
decreased
99%
after universal
recommendation**

Source: [Hepatitis B Vaccine Frequently Asked Questions](#)

Hepatitis B Recommendations

All infants should receive the Hepatitis B birth dose and complete series

- Recommendations are dependent on the birth parent's HBsAg status
 - Generally 3 or 4-dose series at 0,1-2 and 6-18 months



Influenza

- Spread through respiratory droplets when an infected person sneezes, coughs or talks
- Symptoms last about a week- but can be longer

Fever

Sore Throat

Fatigue

Cough

Body Aches

Headache



Influenza Recommendation

Side effects:

- Soreness or redness at injection site
- Mild fever
- Headache

Routinely recommended for all children 6 months and older

- **6 months- 8 years:** 1-dose if they received at least 2 influenza vaccine doses before July 1, 2025.
 - 2-doses 4 weeks apart for children who have received fewer than 2 doses, or unknown history
- **9 years and older:** 1-dose
- **18 years old and solid organ transplant recipients** receiving immunosuppressive medications: high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) are acceptable options


HPV Recommendation

2 or 3-dose series (depending on initial vaccination)

- Age 9-14 years at initial vaccination: 2-dose series at 0, 6-12 months
- Age 15 years or older at initial vaccination: 3-dose series at 0, 1-2 months, 6 months

Side effects:

- Headache
- Tiredness
- Muscle or Joint Pain
- Dizziness
- Fainting



Hepatitis A

- Spread by person-to-person contact or through contaminated food/water.
- Symptoms can last for several months:

Nausea	Jaundice
Fever	Loss of appetite
Vomiting	Inflammation of the liver



30,000 cases/year



95%

1,000 - 17,500 cases/year

Source: [Hepatitis A | Let's Get Real](#)

Hepatitis A Immunization Recommendation



Two-dose series:

- Dose 1: 12-23 months
- Dose 2: At least 6 months after the first dose


Side effects:

- Soreness or redness at injection site
- Mild fever
- Headache
- Feeling tired

MenACWY

Meningococcal disease is uncommon but dangerous

- Can result in hearing loss, brain damage, learning disabilities, limb amputations, kidney damage, death.



1 in 10 who develop meningitis die

Mbaeyi S, Stokley S. Meningococcal Conjugate Vaccine in the United States: Remaining Challenges for Adolescent Vaccination. J Adolesc Health. 2019 Jul;65(1):11-12. doi: <https://doi.org/10.1016/j.jadohealth.2019.04.021>

MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996–2015. Clin Infect Dis 2018;66: 1276–81. <https://doi.org/10.1093/cid/cix993>

MenACWY Vaccine: The Recommendation


**11 - 12
years**

**16
years**

Sources:

<https://www.give2menacwy.org/pdfs/menacwy-factsheet.pdf>

[Meningococcal: The Disease & Vaccines | Children's Hospital of Philadelphia](#)



RSV

- Infants, especially those under 6 months, are more likely have severe RSV disease.
- RSV is the leading cause of hospitalization in infants and toddlers.
 - Up to 80,000 babies in the U.S. are hospitalized with RSV each year.
- Severe RSV can cause permanent lung damage.
- 100 to 300 children die each year from RSV and its complications



80 - 90%
effective at protecting
infants from
hospitalization

Sources:

[Respiratory Syncytial Virus \(RSV\)](#)

[Respiratory Syncytial Virus Infection \(RSV\) | Let's Get Real](#)

RSV Monoclonal Antibody Recommendation









The Recommendation:

- A monoclonal antibody product (either nirsevimab or clesrovimab) is recommended for all infants less than 8 months old born during or entering their first RSV season if:
 - The birth parent did not receive vaccine during pregnancy
 - Birth parents' vaccination status is unknown
 - The infant was born within 14 days of maternal RSV vaccination
- *October through March






Side effects:

- Pain, redness or swelling at injection site.
- Hypersensitivity reactions are a rare side effect that have been reported with similar products.

Resources

	Vaccine preventable disease images available on Immunize.org
	NFID offers information about vaccine-preventable diseases, vaccines, webinars and other resources
	CHOP offers extensive resources for providers and families.
	Public facing website with accessible and engaging information.
	Website with engaging information and resources, including personal stories.
VaccineInformation.org	Public facing website from Immunize.org that presents straightforward information about vaccine-preventable diseases and their vaccines
	Provides clinical guidance and tools for implementation and education.

Resources

	<p>The Evidence Collective provides briefs and resources where public health information is translated by trained health communicators to deliver clear, evidence-based information.</p>
	<p>AAP's Fact Checked series provides facts, evidence and expert comments on circulating misconceptions.</p>
	<p>A campaign built on a research informed approach based on extensive parent and expert interviews and focus groups that offers information for providers and families on vaccine misconceptions, risks versus benefits and more.</p>
	<p>Source of updated infectious disease news and analysis.</p>
	<p>Site offers analysis and assistance with public health communications through podcasts, social media posts and more; has a free vaccine education module.</p>

Making the Case and Navigating the Changes

Debunking Common Misconceptions



Doctors are paid bonuses for how many people they can vaccinate. Time to ask if a doctor recommends a shot for another doctor and if they refuse then make them write on your chart that they refuse.



Because they are bought and paid for by big pharmaceutical



Real Vermonters used to think for themselves. None of these vaccines have been tested appropriately. We are all born perfect and then big pharma gets a hold of our babies.

Misconception: Doctors make a lot of money off vaccines.

Fact 1: Vaccines are not a significant source of income for provider offices.

Fact 2: Providers make recommendations to protect your child based on decades of medical evidence.

- Physicians (and scientists) are required by law to disclose potential financial conflicts of interest.
 - [Home | OpenPayments](#) -- can search by provider, teaching hospital or company
- Reimbursement for vaccine administration varies by payer.
 - In Vermont, \$21.22 is the administration fee cap through VVPP.
- Performance incentives cover a broad collection of best practices.

Trusted Messengers: Social Media Recommendations



Dr. Mona Amin, MD, FAAP
Pediatrician/Certified Lactation
Consultant (IBCLC) in Florida



Dr. Ari Brown, MD, FAAP
Pediatrician in Texas



Dr. Tommy Martin, MD, FAAP
Internal Medicine/Pediatric
Physician in Massachusetts



Dr. Alok Patel, MD, FAAP
Pediatric Hospitalist in California



Dr. Zachary Rubin, MD, FAAP
Pediatrician/Allergist and
Immunologist in Illinois



Dr. Rebecca Bell, MD
Pediatric Critical Care
Physician at UVM





Dr. Tracy Tyson, MD
Pediatric Critical Care
Physician at Monarch
Maples Pediatrics

[Follow Pediatricians for
Trustworthy Content on
Children's Health -
HealthyChildren.org](https://www.healthychildren.org/)

Childhood Immunizations Matter

Over the last 3 decades, childhood immunizations prevented:



[Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program – United States, 1994–2023 | MMWR](#)


Vaccines Work!

DISEASE	PRE-VACCINE ERA ESTIMATED ANNUAL MORBIDITY
Diphtheria	21,053 ¹
<i>H. influenzae</i> serotype B (invasive, <5 years of age)	20,000 ¹
Hepatitis A	117,333 ¹
Hepatitis B (acute)	66,232 ¹
Measles	530,217 ¹
Meningococcal disease (all serotypes)	2,886 ⁴
Mumps	162,344 ¹
Pertussis	200,752 ¹
Pneumococcal disease (invasive, <5 years of age)	16,069 ¹
Polio (paralytic)	16,316 ¹
Rotavirus (hospitalizations, <5 years of age)	60,000 ^{5,**}
Rubella	47,745 ¹
Congenital Rubella Syndrome	152 ¹
Smallpox	29,005 ¹
Tetanus	580 ¹
Varicella	4,085,120 ¹

[Vaccines Work!](#)


Image from [NDSU CIRE](#).

Vermont Department of Health



Vaccines Work!

DISEASE	PRE-VACCINE ERA ESTIMATED ANNUAL MORBIDITY	MOST RECENT REPORTS OR ESTIMATES OF U.S. CASES	PERCENT DECREASE
Diphtheria	21,053 ¹	1 ²	>99%
<i>H. influenzae</i> serotype B (invasive, <5 years of age)	20,000 ¹	17 ²	>99%
Hepatitis A	117,333 ¹	(est) 3,300 ³	97%
Hepatitis B (acute)	66,232 ¹	(est) 14,400 ³	78%
Measles	530,217 ¹	121 ^{2,*}	>99%
Meningococcal disease (all serotypes)	2,886 ⁴	312 ²	89%
Mumps	162,344 ¹	386 ²	>99%
Pertussis	200,752 ¹	3,044 ²	98%
Pneumococcal disease (invasive, <5 years of age)	16,069 ¹	1,117 ²	93%
Polio (paralytic)	16,316 ¹	1 ²	100%
Rotavirus (hospitalizations, <5 years of age)	60,000 ^{5,**}	(est) 12,000 ^{6,**}	80%**
Rubella	47,745 ¹	7 ²	>99%
Congenital Rubella Syndrome	152 ¹	0 ²	>99%
Smallpox	29,005 ¹	0 ²	100%
Tetanus	580 ¹	26 ²	96%
Varicella	4,085,120 ¹	4,348 ²	>99%



Vaccines Work!

Image from [NDSU CIRE](#).


Vermont Department of Health

Smallpox: 0
Congenital Rubella Syndrome: 0

Gratitude



Vaccines are still the social norm



- State-level immunization coverage in Vermont for MMR vaccination is above national levels.
- Vermont immunization coverage is regularly higher than national averages and other states.
 - Vermont's up-to-date HPV coverage for 13-17 years is 71.7% compared to the national rate of 62.9%
 - For the 2024-2025 season, Vermont ranked 3rd for nirsevimab administration.

What's Next?

- 1 Consider posting a public communication to your webpage**
- 2 Maintain strong recommendations in alignment with Vermont/AAP recommendations**
- 3 Build an immunization culture in your office**
- 4 Communicate with VDH and partners as needs arise**

Questions





Thank you!

Let's stay in touch

Email: AHS.VDHIimmunizationProgram@vermont.gov

Web: healthvermont.gov

Social: [@healthvermont](https://twitter.com/healthvermont)